larotrectinib sulfate

{
  "id": "MLC-T-ONC-004725",
  "term": "larotrectinib sulfate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults and children with certain types of solid tumors that have spread or cannot be removed by surgery and have the NTRK gene fusion. It is also being studied in the treatment of other types of cancer. Larotrectinib sulfate blocks the TRK protein, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called LOXO-101, Trk inhibitor LOXO-101, and Vitrakvi.",
    "An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival."
  ],
  "synonyms": [
    "LOXO-101",
    "Trk inhibitor LOXO-101",
    "Vitrakvi"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/larotrectinib-sulfate/"
}